GleamWall
中文EN

TARA Protara Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1359931 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-48.3%
TTM EPS YoY-0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-57.4%
ROA-52.1%
ROIC (approx.)-57.3%
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.00x
Current ratio9.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$42.63M$31.70M
SG&A expense$21.92M$17.45M
Operating income-$64.55M-$49.15M
Pretax income$57.35M$44.56M
Net income-$57.44M-$44.60M
EBITDA-$64.19M-$48.82M
EPS (basic)-1.34-2.17
EPS (diluted)-1.34-2.17
Weighted avg. shares (diluted)42.84M20.59M
Balance sheet
Cash & equivalents$49.66M$163.54M
Short-term investments$105.90M$7.49M
Current assets$159.50M$172.16M
PP&E, net$759,000$1.03M
Total assets$209.47M$181.45M
Current liabilities$10.94M$10.96M
Total liabilities$13.06M$14.32M
Shareholders' equity$196.41M$167.13M
Shares outstanding53.59M35.04M
Cash flow statement
Operating cash flow-$56.37M-$35.81M
Capital expenditure$94,000$63,000
Free cash flow-$56.46M-$35.87M
Investing cash flow-$139.49M$19.16M
Financing cash flow$82.72M$139.87M
Depreciation & amortization$362,000$332,000
Stock-based compensation$3.83M$4.12M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.